References
- Govan JR, Deretic V. Microbial pathogenesis in cystic fibrosis: mucoid Pseudomonas aeruginosa and Burkholderia cepacia. Microbiol Rev 1996; 60: 539–74
- Burns JL, Saiman L, Whittier S, Larone D, Krzewinski J, Liu Z, et al. Comparison of agar diffusion methodologies for antimicrobial susceptibility testing of Pseudomonas aeruginosa isolates from cystic fibrosis patients. J Clin Microbiol 2000; 38: 1818–22
- Shawar RM, MacLeod DL, Garber RL, Burns JL, Stapp JR, Clausen CR, et al. Activities of tobramycin and six other antibiotics against Pseudomonas aeruginosa isolates from patients with cystic fibrosis. Antimicrob Agents Chemother 1999; 43: 2877–80
- Balke B, Hogardt M, Schmoldt S, Hoy L, Weissbrodt H, Häussler S. Evaluation of the E test for the assessment of synergy of antibiotic combinations against multiresistant Pseudomonas aeruginosa isolates from cystic fibrosis patients. Eur J Clin Microbiol Infect Dis 2006; 25: 25–30
- Chen Y, Garber E, Zhao Q, Ge Y, Wikler MA, Kaniga K, et al. In vitro activity of doripenem (S-4661) against multidrug-resistant Gram-negative bacilli isolated from patients with cystic fibrosis. Antimicrob Agents Chemother 2005; 49: 2510–1
- Burns JL, Saiman L, Whittier S, Krzewinski J, Liu Z, Larone D, et al. Comparison of two commercial systems (Vitek and MicroScan-WalkAway) for antimicrobial susceptibility testing of Pseudomonas aeruginosa isolates from cystic fibrosis patients. Diagn Microbiol Infect Dis 2001; 39: 257–60
- Joyce LF, Downes J, Stockman K, Andrew JH. Comparison of five methods, including the PDM Epsilometer Test (E Test), for antimicrobial susceptibility testing of Pseudomonas aeruginosa. J Clin Microbiol 1992; 30: 2709–13
- Marley EF, Mohla C, Campos JM. Evaluation of E-test for determination of antimicrobial MICs for Pseudomonas aeruginosa isolates from cystic fibrosis patients. J Clin Microbiol 1995; 33: 3191–3
- Sader HS, Fritsche TR, Jones RN. Accuracy of three automated systems (MicroScan WalkAway, Vitek, and Vitek 2) for susceptibility testing of Pseudomonas aeruginosa against five broad-spectrum beta-lactam agents. J Clin Microbiol 2006; 44: 1101–4
- Saiman L, Burns JL, Whitter S, Krzewinski J, Marshall SA, Jones RN. Evaluation of reference dilution test methods for antimicrobial susceptibility testing of Pseudomonas aeruginosa strains isolated from patients with cystic fibrosis. J Clin Microbiol 1999; 37: 2987–91
- Clinical and Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard M7-A7. Wayne, PA: Clinical and Laboratory Standards Institute; 2006.
- Horii T, Muramatsu H, Morita M, Maekawa M. Characterization of Pseudomonas aeruginosa isolates from patients with urinary tract infections during antibiotic therapy. Microb Drug Resist 2003; 9: 223–9
- Hirakata Y, Izumikawa K, Yamaguchi T, Takemura H, Tanaka H, Yoshida R, et al. Rapid detection and evaluation of clinical characteristics of emerging multiple-drug-resistant Gram-negative rods carrying the metallo-β-lactamase gene blaIMP. Antimicrob Agents Chemother 1998; 42: 1267–8
- Livermore DM. Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare?. Clin Infect Dis 2002; 34: 634–40